Researchers at the New York University School of Medicine have identified a treatment that they hope will extend the life expectancy of implants. In animal experiments, treatment with agonists of the adenosine 2A receptor prevented the inflammation and subsequent bone loss that is one of the leading causes of prosthesis loosening and implant failure. Read More
Veloxis Pharmaceuticals A/S is betting the farm on its late-stage organ transplant rejection drug LCP-Tacro and exiting from all other development activities in an effort to stretch out its rapidly dwindling cash resources. Read More
• Crescendo Therapeutics LLC, of Vista, Calif., had U.S. marshals seize supplies of HybriSil (methylpredinsolone acetate 1 percent in silicone gel) on a warrant issued by the U.S. District Court for the Southern District of California at the request of the FDA. Read More
• Insmed Inc., of Monmouth Junction, N.J., began screening patients for TARGET-NTM (Treatment with ARIKACE to Realize Greater Efficacy Trial), its U.S. Phase II trial of Arikace (liposomal amikacin for inhalation) in nontuberculous mycobacterial lung disease. Read More
• Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said the European Medicines Agency accepted the submission of a marketing authorization application for alogliptin, a selective dipeptidyl peptidase IV inhibitor in Type II diabetes. Read More
• Shire plc, of Dublin, Ireland, reported Phase III results demonstrating the long-term maintenance efficacy of lisdexamfetamine dimesylate (LDX) in children and adolescents, ages 6 to 17, with attention deficit hyperactivity disorder (ADHD). Read More
